WO2000069857A1 - Process for making fused-ring imidazo-containing compounds - Google Patents
Process for making fused-ring imidazo-containing compounds Download PDFInfo
- Publication number
- WO2000069857A1 WO2000069857A1 PCT/US2000/013417 US0013417W WO0069857A1 WO 2000069857 A1 WO2000069857 A1 WO 2000069857A1 US 0013417 W US0013417 W US 0013417W WO 0069857 A1 WO0069857 A1 WO 0069857A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- aryl
- alkyl
- ring
- nil
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 123
- 238000000034 method Methods 0.000 title claims abstract description 33
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 17
- 125000003118 aryl group Chemical group 0.000 claims description 36
- 239000002904 solvent Substances 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 30
- 125000000623 heterocyclic group Chemical group 0.000 claims description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 12
- 150000001408 amides Chemical group 0.000 claims description 7
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 230000002140 halogenating effect Effects 0.000 claims description 4
- 239000000376 reactant Substances 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 229910020667 PBr3 Inorganic materials 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 229910007161 Si(CH3)3 Inorganic materials 0.000 abstract description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 72
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 40
- 239000011541 reaction mixture Substances 0.000 description 37
- 239000000243 solution Substances 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
- 238000004587 chromatography analysis Methods 0.000 description 16
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 238000007792 addition Methods 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- 125000005842 heteroatom Chemical group 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 12
- 238000010992 reflux Methods 0.000 description 11
- 239000012300 argon atmosphere Substances 0.000 description 10
- 239000012298 atmosphere Substances 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 5
- 239000011698 potassium fluoride Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 125000005257 alkyl acyl group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000005251 aryl acyl group Chemical group 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 4
- KDFDOINBXBEOLZ-UHFFFAOYSA-N 2-phenylpropan-2-amine Chemical compound CC(C)(N)C1=CC=CC=C1 KDFDOINBXBEOLZ-UHFFFAOYSA-N 0.000 description 3
- GUUVPOWQJOLRAS-UHFFFAOYSA-N Diphenyl disulfide Chemical compound C=1C=CC=CC=1SSC1=CC=CC=C1 GUUVPOWQJOLRAS-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000001769 aryl amino group Chemical group 0.000 description 3
- 150000007860 aryl ester derivatives Chemical class 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 238000006798 ring closing metathesis reaction Methods 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- FEZKXHIGXMGTNI-UHFFFAOYSA-N 1H-imidazol-2-ylstannane Chemical compound [SnH3]c1ncc[nH]1 FEZKXHIGXMGTNI-UHFFFAOYSA-N 0.000 description 2
- HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 0 CC(*)=C(*)c1cnc(*)[n]1* Chemical compound CC(*)=C(*)c1cnc(*)[n]1* 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 2
- -1 phospho Chemical class 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- PHBUVWINFJHUJL-UHFFFAOYSA-N (4-methoxy-2-nitrophenyl) trifluoromethanesulfonate Chemical compound COC1=CC=C(OS(=O)(=O)C(F)(F)F)C([N+]([O-])=O)=C1 PHBUVWINFJHUJL-UHFFFAOYSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- QMYZFKWLASANKX-UHFFFAOYSA-N 2-(2-bromo-4,5-dimethoxyphenyl)ethanol Chemical compound COC1=CC(Br)=C(CCO)C=C1OC QMYZFKWLASANKX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- IZGCJFUQSIQCTM-UHFFFAOYSA-N CC(C)(c1ccccc1)Nc1ncc(-c(c(N2)c3)ccc3OC)[n]1CC2=O Chemical compound CC(C)(c1ccccc1)Nc1ncc(-c(c(N2)c3)ccc3OC)[n]1CC2=O IZGCJFUQSIQCTM-UHFFFAOYSA-N 0.000 description 1
- SLHNXQYMSFGNOI-UHFFFAOYSA-N COc1ccc(-c([n]2CC(N3)=O)cnc2S(c2ccccc2)(=O)=O)c3c1 Chemical compound COc1ccc(-c([n]2CC(N3)=O)cnc2S(c2ccccc2)(=O)=O)c3c1 SLHNXQYMSFGNOI-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000005792 cardiovascular activity Effects 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- DDKMFOUTRRODRE-UHFFFAOYSA-N chloromethanone Chemical compound Cl[C]=O DDKMFOUTRRODRE-UHFFFAOYSA-N 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 125000004474 heteroalkylene group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000020883 regulation of protein transport Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- SYUVAXDZVWPKSI-UHFFFAOYSA-N tributyl(phenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CC=C1 SYUVAXDZVWPKSI-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
- C07F7/083—Syntheses without formation of a Si-C bond
Definitions
- the subject invention relates to processes for making certain substituted fused-ring imidazo compounds.
- Some fused-ring imidazo compounds have pharmacological activity in processes known to be associated with one or more of cardiovascular activity, inflammatory mechanisms, oncology, and regulation of protein transport from cells.
- the subject invention processes are useful for making such compounds.
- each -Q2- is nil or -C(O)-;
- each -R is independently selected from hydrogen, alkyl, aryl, and heterocycle;
- each -RI is independently selected from hydrogen, alkyl, aryl, heterocycle, or the two Rl 's are attached to form a cycloalkenyl, aryl or heterocyclic ring; the process comprising the following Steps:
- m, n, -Ql- and -RI are the same as for compound (X); and -XI is selected from -Cl, -Br, -I, -OH and -COOH;
- -X2 being -Cl or -Br or -I; (ii) if -XI is -COOH, treating compound (2) with phosgene or oxalyl chloride in solvent, whereby -XI is converted to -X2, -X2 being -
- Step (B) if -XI is -Cl or -Br or -I, or if the conversion to compound (I) in Step (A) is insufficient, treating compound (2) or the reaction product of Step (A), respectively, with 11BU4NF in solvent, whereby conversion to compound (I) occurs.
- the subject invention also involves processes having additional Steps before and/or after Steps (A) and/or (B).
- the subject invention also involves combinatorial libraries of compounds made according to subject processes.
- alkyl means a hydrocarbon chain which is branched, linear or cyclic, saturated or unsaturated (but not aromatic), substituted or unsubstituted.
- alkyl may be used alone or as part of another word where it may be shortened to "alk” (e.g., in alkoxy, alkylacyl).
- Preferred linear alkyl have from one to about twenty carbon atoms, more preferably from one to about ten carbon atoms, more preferably still from one to about six carbon atoms, still more preferably from one to about four carbon atoms; most preferred are methyl or ethyl.
- Preferred cyclic and branched alkyl have from three to about twenty carbon atoms, more preferably from three to about ten carbon atoms, more preferably still from three to about seven carbon atoms, still more preferably from three to about five carbon atoms.
- Preferred cyclic alkyl have one hydrocarbon ring, but may have two, three, or more, fused or spirocycle hydrocarbon rings.
- Preferred alkyl are unsaturated with from one to about three double or triple bonds, preferably double bonds; more preferably they are mono-unsaturated with one double bond. Still more preferred alkyl are saturated. Saturated alkyl are referred to herein as "alkanyl".
- alkyl unsaturated only with one or more double bonds (no triple bonds) are referred to herein as "alkenyl”.
- Preferred substituents of alkyl include halo, alkyl, aryl, heterocycle, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, alkylamino, arylamino, amide, alkylamide, arylamide, formyl, alkylacyl, arylacyl, carboxy and its alkyl and aryl esters and amides, sulfo, alkylsulfo, arylsulfo, sulfino, alkylsulf ⁇ no, arylsulfino, phospho, alkylphospho, arylphospho, phosphino, alkylphosphino, arylphosphino, nitro, and cyano.
- Substituents of cycloalkyl
- heteroatom means a nitrogen, oxygen, or sulfur atom.
- alkylene means an alkyl which connects two other moieties, “heteroalkylene” means an alkylene having one or more heteroatoms in the connecting chain.
- aryl means an aromatic hydrocarbon ring (or fused rings) which is substituted or unsubstituted.
- aryl may be used alone or as part of another word (e.g., in aryloxy, arylacyl).
- Preferred aryl have from six to about fourteen, preferably to about ten, carbon atoms in the aromatic ring(s), and a total of from about six to about twenty, preferably to about twelve, carbon atoms.
- Preferred aryl is phenyl or naphthyl; most preferred is phenyl (Ph).
- Preferred substituents of aryl include halo, alkyl, aryl, heterocycle, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, alkylamino, arylamino, amide, alkylamide, arylamide, formyl, alkylacyl, arylacyl, carboxy and its alkyl and aryl esters and amides, sulfo, alkylsulfo, arylsulfo, sulfino, alkylsulfino, arylsulfino, phospho, alkylphospho, arylphospho, phosphino, alkylphosphino, arylphosphino, nitro, and cyano.
- Substituents of aryl also include cycloalkyl and heterocycle rings which are fused with the aryl ring or rings. Also, unsubstituted aryl are
- heterocycle or “heterocyclic” means a saturated, unsaturated or aromatic cyclic hydrocarbon ring (or fused rings) with one or more heteroatoms in the hydrocarbon ring(s).
- Preferred heterocycles have from one to about six heteroatoms in the ring(s), more preferably one or two or three heteroatoms in the ring(s).
- Preferred heterocycles have from three to about fourteen, preferably to about ten, carbon plus heteroatoms in the ring(s), more preferably from three to about seven, more preferably still five or six, carbon plus heteroatoms in the rings(s); and a total of from three to about twenty carbon plus heteroatoms, more preferably from three to about ten, more preferably still five or six, carbon plus heteroatoms.
- Preferred heterocycles have one ring, but may have two, three, or more, fused rings. More preferred heterocycle rings include those which are one ring with 5 or 6 carbon plus heteroatoms in the ring with no more than three ring heteroatoms, no more than two of which are O and S.
- Such preferred 5- or 6-ring atom heterocycles are preferably saturated, unsaturated with one or two double bonds, or aromatic.
- Such preferred 5- or 6-ring atom heterocycles are preferably a single ring; or fused with a 3- to 6-ring atom hydrocarbon ring which is saturated, unsaturated with one double bond, or aromatic (phenyl); or fused with another such 5- or 6-ring atom heterocyclic ring.
- Heterocycles are unsubstituted or substituted. Preferred heterocycle substituents are the same as for alkyl.
- m is an integer from 0 to about 6, preferably from 0 to about 2, more preferably 0 or 1 ; n is an integer from 0 to about 6, preferably from 0 to about 2, more preferably 0 or 1; m + n is from 0 to 12, preferably from 0 to about 4, more preferably from 1 to about 3, more preferably still 2 or 3.
- each -R is independently selected from hydrogen, alkyl, aryl, and heterocycle.
- Non-hydrogen -R are preferably selected from phenyl, heterocycle having 5 or 6 ring atoms including 1 or 2 heteroatoms, and alkyl having from 1 to about 6 carbon atoms; such R are unsubstituted or substituted, preferably unsubstituted.
- no more than 2 of all the -R's is other than hydrogen, more preferably no more than 1 ; more preferably still all -R's are hydrogen.
- each -RI is independently selected from hydrogen, alkyl, aryl and heterocycle, or both -Rl 's are attached to form a cycloalkenyl, aryl or heterocyclic ring.
- the two -Rl 's are attached to form a cycloalkenyl, aryl, or heterocyclic ring; more preferably a cycloalkenyl or aryl ring; more preferably still an aryl ring, especially phenyl.
- substituents are preferably attached to the phenyl ring by a heteroatom, the heteroatom preferably being oxygen; such substituents are preferably alkoxy, especially methoxy.
- m + n is preferably from 1 to about 4, more preferably from 1 to about 3.
- -XI is selected from -Cl, -Br, -I, -OH and -COOH. If -XI is -OH, then -X2 can be -OMs or OTs, and -Q2- is nil. Alternatively, if - XI is -OH, -X2 can be -Cl or -Br or -I, and -Q2- is nil. If -XI is -COOH, then -X2 is - C(O)Cl, and -Q2- is -C(O)-. If -XI is -Cl or -Br or -I, Step (A) is skipped, and -X2 is the same as -XI (compound (2) and compound (3) are the same).
- compound (2) can be treated with either methylsulphonyl chloride (MsOCl) or p-toluenesulfonyl chloride (TsOCl), preferably in the presence of base (e.g. triethylamine (Et ⁇ N)), in solvent, preferably dichlorolmethane.
- MsOCl methylsulphonyl chloride
- TsOCl p-toluenesulfonyl chloride
- base e.g. triethylamine (Et ⁇ N)
- solvent preferably dichlorolmethane.
- This reaction is preferably carried out under an inert atmosphere, more preferably under an argon atmosphere.
- the MsOCl or TsOCl is preferably added slowly, preferably over a period of up to about 2 h, more preferably from about 1/4 h about 1 h. More preferably still over about 1/2 h.
- the temperature of the reaction mixture is preferably from about -20 °C to about 25 °C, more preferably about 0 °C.
- the reaction mixture is preferably warmed to a temperature of from about 0 °C to about 40 °C, more preferably to about room temperature; at this temperature, the reaction mixture is stirred preferably for from about 1/2 h to about 6 h, more preferably for about 1 h.
- halogenating reaction conditions that are compatible with compounds of structure (2), (3), and (!) are suitable.
- Preferred halogenation reactions are selected from the following:
- Compound (2) can be treated with thionyl chloride (SOCI2), preferably in the presence of base (e.g., triethylamine), in solvent, preferably dichloromethane, to produce compound (3) wherein -X2 is Cl.
- SOCI2 thionyl chloride
- This reaction is preferably carried out under an inert atmosphere, more preferably under an argon atmosphere.
- the thionyl chloride is preferably added slowly, preferably over a period of up to about 2 h, more preferably from about 1/4 h about 1 h. More preferably still over about 1/2 h.
- the temperature of the reaction mixture is preferably from about -20 °C to about 25 °C, more preferably about 0 °C.
- the reaction mixture is preferably warmed to a temperature of from about 0 °C to about 40 °C, more preferably to about room temperature; at this temperature, the reaction mixture is stirred preferably for from about 1/2 h to about 6 h, more preferably for about 1 h.
- Compound (2) can be treated with NBS, preferably in the presence of triphenylphosphine (Ph3P), in solvent, preferably dimethyl formamide (DMF), or with tribromophosphine (PBr3), preferably in the presence of base (e.g., pyridine), in solvent, preferably dichloromethane, to produce compound (3) wherein -X2 is -Br.
- Ph3P triphenylphosphine
- PBr3 tribromophosphine
- base e.g., pyridine
- This reaction is preferably carried out under an inert atmosphere, more preferably under a nitrogen atmosphere.
- the temperature of the reaction mixture is preferably from about 0 °C to about 40 °C, more preferably about 20 °C.
- the reaction mixture is stirred preferably for from about 1/2 h to about 12 h, more preferably for about 2 h.
- Compound (2) can be treated with sodium iodide (Nal) or potassium iodide (KI), preferably in the presence of strong acid (e.g., phosphoric acid, sulfuric acid), in solvent, preferably DMF, to produce compound (3) wherein -X2 is -I.
- the temperature of the reaction mixture is preferably from about 0 °C to about 90 °C, more preferably about 20 °C.
- the reaction mixture is stirred preferably for from about 1 h to about 12 h, more preferably for about 2 h.
- compound (2) is treated with phosgene (CI2CO) or oxalyl dichloride ((ClCO)2) in solvent, preferably dichloromethane.
- This reaction is preferably carried out under an inert atmosphere, more preferably under an argon atmosphere.
- the phosgene or oxalyl dichloride is preferably added slowly, preferably over a period of up to about 2 h, more preferably from about 1/4 h about 1 h. More preferably still over about 1/2 h.
- the temperature of the reaction mixture is preferably from about -20 °C to about 25 °C, more preferably about
- reaction mixture is preferably warmed to a temperature of from about 0 °C to about 40 °C, more preferably to about room temperature; at this temperature, the reaction mixture is stirred preferably for from about 1/2 h to about 6 h, more preferably for about 1 h.
- Step (A) -XI is converted to -X2. If -XI is -OH, then -X2 is selected from - OMs, -OTs, -Cl, -Br and -I. If -XI is -COOH, then -X2 is -C(O)Cl.
- Step (A) is not needed, and -X2 is the same as -XI, i.e., compound (2) is also compound (3). In this case, only Step (B) is needed to produce compound (1).
- Step (A) the -SEM protective group on the imidazo nitrogen may be split off and the reactive -X2 moiety may spontaneously react at that position to close the ring, thus forming compound (1). If this ring closure is sufficient in Step (A), then Step (B) is not needed; otherwise Step (B) is used to achieve sufficient ring closure. Step (B)
- Step (A) solvent is removed from the final Step (A) reaction mixture, preferably by evaporation under vacuum at room temperature.
- Compound (3) or the reaction product from Step (A) is treated with tetrabutylammonium fluoride (11BU4NF) in solvent, preferably tetrahydrofurane (THF).
- tetrabutylammonium fluoride 11BU4NF
- solvent preferably tetrahydrofurane (THF).
- This treatment is preferably carried out at a temperature of from about 0 °C to about 60 °C, more preferably at about room temperature, preferably for a period of from about 1/2 h to about 12 h, more preferably for about 4 h.
- Compound (i) is preferably isolated and purified from the reaction mixture of Step (A) or/and Step (B) by evaporating off organic solvent, washing the product with water and/or aqueous solutions, separating the organic layer from the aqueous layer, drying off the organic layer by evaporation, and purifying by chromatography.
- -Z is -Br, -I, or -OTf, preferably -Br.
- -J is alkanyl having from 1 to about 4 carbon atoms; prefe ⁇ ed J is methyl or n-butyl.
- Step (C) compound (4) and compound (5) are reacted in solvent, preferably dioxane, preferably in the presence of Pd(PPh-3)4 catalyst, to produce compound (2).
- a small amount of a radical scavenger, preferably 2,6-di-tert-butyl-4-methylphenol (DTBMP) is included in the reaction mixture for Step (C).
- DTBMP 2,6-di-tert-butyl-4-methylphenol
- -Z is trifluoromethanesulfonate (-OTf)
- LiCl lithium chloride
- the components of the reaction mixture are preferably combined at about room temperature; then the reaction mixture is heated to about reflux temperature.
- the reaction mixture is held at about reflux temperature for a period of from about 2 h to about 24 h, preferably for about 5 h.
- the reaction mixture is preferably retained under an inert atmosphere, preferably under an argon atmosphere during Step (C).
- the reaction mixture is preferably cooled to about room temperature.
- the cooled reaction mixture is preferably treated with a mixture of ether and saturated aqueous potassium fluoride solution, preferably about a 1 : 1 mixture, preferably for from about 1 h to about 24 h, more preferably for about 15 h.
- Purified compound (2) is obtained from the reaction mixture, preferably by filtration, ether washing, water and aqueous solution washing, drying, and purifying by chromatography.
- -Q3- is a subset of the moieties of -Q1-; -Q3- is selected from -O-, -S-, -NR-, - NR-C(O)-, and -OC(O)-; preferably from -O-, -S-, and -NR-.
- -Y is -NHR, -OH, or -SH; preferably -NHR or -OH; more preferably -OH.
- -W is -I, -Br, or -C(O)V, preferably -Br or -C(O)V, more preferably -Br.
- -V is -OH, -Cl, or -Br, preferably Cl.
- Step (O) In Step (D) of Scheme -HI, compound (6) and compound (5) are reacted in solvent, preferably dioxane, preferably in the presence of Pd(PPh3)4 catalyst to produce compound (7).
- solvent preferably dioxane
- Pd(PPh3)4 catalyst The preferred conditions for Step (D) of Scheme III are the same as those for Step (C) of Scheme ⁇ .
- Step (E) compound (7), and compound (8) are reacted, preferably in the presence of a base, in solvent, preferably dichlorolmethane, to produce compound (2a).
- a base in solvent, preferably dichlorolmethane
- Preferred bases useful for this step include sodium carbonate and triethylamine; more prefe ⁇ ed is triethylamine.
- This step is preferably carried out at a temperature of from about 0 °C to about 45 °C, more preferably at about room temperature, preferably for a period of from about 2 h to about 14 h, more preferably for about 6 h.
- the subject invention processes include the preparation of compound (9) from compound (X) or compound (11) as depicted Scheme IV:
- -R2 may be hydrogen in which case Steps (G) and (H) are not used.
- -R2 is selected from hydrogen, halo, alkyl, aryl, heterocycle, carboxy and its alkyl esters and amides.
- Prefe ⁇ ed -R2 is selected from hydrogen, halo, C1-C4 alkyl, and phenyl. More prefe ⁇ ed -R2 is selected from hydrogen and unsubstituted and substituted phenyl; substituents on such phenyl are preferably selected from hydroxy, alkoxy, thio and alkylthio. Most prefe ⁇ ed -R2 is hydrogen.
- -R3 is selected from hydrogen, alkyl, aryl, and heterocycle.
- Prefe ⁇ ed -R3 is selected from alkyl, aryl, and heterocycle. More prefe ⁇ ed -R3 is unsubstituted and substituted phenyl and benzyl.
- substituents for such phenyl and benzyl are selected from halo, C1-C4 alkyl, aryl, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, alkylamino, arylamino, formyl, alkylacyl, arylacyl, carboxy and its alkyl and aryl esters, amides, thioesters and thioamides.
- More prefe ⁇ ed -R3 is benzyl, wherein the alpha carbon of the benzyl is unsubstituted or substituted; prefe ⁇ ed substituents are selected from alkyl (preferably C1-C4), aryl and heterocycle.
- Step (F) compound (1) or compound ( ⁇ ) is combined with compound (12) and n-butyllithium (nBuLi) in solvent, preferably tetrahydrofuran, to produce compound (9).
- Compound (12) is preferably dissolved in solvent first, and the resulting solution is cooled to a temperature of from about -30 °C to about 5 °C, preferably about 0 °C.
- the solution is preferably under an inert atmosphere, more preferably under an argon atmosphere.
- nBuLi is preferably added slowly to the solution over a period of from about 0.2 h to about 1 h, more preferably over a period of about 0.5 h.
- the resulting mixture being sti ⁇ ed for a period of from about 1/2 h to about 1 h, more preferably about 3/4 h.
- Compound (X) or compound (11) dissolved in solvent, preferably THF, is then added.
- the reaction mixture is preferably warmed to room temperature, and then preferably heated to about reflux temperature for a period of from about 2 h to about 24 h, more preferably for about 12 h.
- the reaction mixture is preferably quenched with methanol.
- Compound (9) is preferably purified from the reaction mixture by evaporating the solvent, redesolving in solvent, preferably dichloromethane, washing with water and aqueous solutions, drying, and purifying by chromatography.
- solvent preferably dichloromethane
- a non-hydrogen -R2 is optionally obtained on compound (9) by performing optional Steps (G) and (H) of Scheme IV.
- Step (G) compound (1) and N-bromosuccinimide (NBS) are combined in solvent, preferably carbon tetrachloride.
- a radical initiator preferably benzoyl peroxide, is preferably added.
- the reaction mixture is heated to a temperature, preferably from about 0 °C to about 100 °C, more preferably about 90 °C.
- the reaction mixture is held at 00/69857
- this elevated temperature for a period of from about 5 min to about 120 min, more preferably for about 10 min.
- Purified compound (10) is preferably obtained by filtration, evaporation, and purification by chromatography.
- Step (H) compound (10) is combined with compound (13) or compound (14) in the presence of Pd(PPh3)4 catalyst in solvent, preferably toluene, to produce compound (11).
- a small amount of radical scavenger, preferably DTBMP, is preferably added to the reaction mixture of Step (H).
- the reaction mixture is heated, preferably to reflux, under an inert atmosphere, preferably a nitrogen atmosphere, preferably for a period of from about 3 h to about 24 h, more preferably for about 6 h.
- the reaction mixture is preferably cooled to about room temperature.
- Purified compound (11) is obtained from the reaction mixture, preferably by extraction, treating with aqueous KF, filtration, washing with water and aqueous solutions, extracting, drying, and purification by chromatography.
- Scheme V The subject invention processes optionally includes one or more additional steps to produce compound (5), as depicted in Scheme V:
- Compound (15), imidazole, is reacted with SEM-CI, preferably in the presence of sodium hydride, in solvent, preferably dimethylformamide (DMF), preferably under an inert atmosphere, preferably at a temperature of from about -20 °C to about 60 °C, more preferably at about room temperature, preferably for a period of from about 1/2 h to about 12 h, more preferably for about 2 h, to produce compound (16).
- solvent preferably dimethylformamide (DMF)
- Compound (16) is reacted with phenyldisulfide, preferably in the presence of n- butyllithium, in solvent, preferably THF, preferably at a temperature of from about -80 °C to about 25 °C, more preferably starting at a temperature of about -80 °C and ending at about room temperature, preferably for a period of from about 1/2 h to about 6 h, more preferably for a period of about 1/2 h after addition of the n-butyllithium at about -80 °C, for about 1 h after addition of the phenyldisulfide at about 0 °C, and for about 1 h at about room temperature, to produce compound (17).
- solvent preferably THF
- Compound (17) is reacted with an oxidizing agent, preferably MCPBA, in solvent, preferably dichloromethane, preferably under an inert atmosphere, preferably at a temperature of from about 0 °C to about 40 °C, more preferably at about room temperature, preferably for a period of from about 2 h to about 24 h, more preferably for about 15 h, to produce compound (18).
- an oxidizing agent preferably MCPBA
- solvent preferably dichloromethane
- Compound (18) is reacted with trialkyltin chloride, preferably tributyltin chloride, in solvent, preferably THF, preferably in the presence of n-butyllithium, preferably under inert atmosphere, preferably at a temperature of from about -80 °C to about 40 °C, more preferably at about room temperature, preferably for a period of from about 1/2 h to about 6 h, more preferably for a period of about 1/2 h after the addition of n-butyllithium at about -80 °C, for about 1 h after addition of tributyltin chloride at about 0 °C, and for about 4 h at room temperature, to produce compound (5).
- solvent preferably THF
- n-butyllithium preferably under inert atmosphere
- Pd(PPh3)4 (0.0177g, 0.015 mmol) is added to a solution of stannylimidazole D (0.51 g, 0.80 mmol), 4,5-dimethoxy-2-(2-hydroxyethyl)phenyl bromide E (0.33 g, 1.1 mmol), and LiCl (0.087 g, 2.1 mmol) in anhydrous dioxane (4.0 mL) at room temperature.
- the reaction is cooled to room temperature and treated with a 1 : 1 mixture of ether and saturated aqueous KF solution (10 mL) for 15 hours. Progress is monitored by TLC (hexane/EtOAc, 3:1). The mixture is filtered through a pad of Celite with ether rinses. The filtrate is washed with water (3 x 12 mL), brine (3 x 12 mL), dried (MgSO4), filtered, evaporated in vacuo, and purified by chromatography (silica gel, hexane/EtOAc, 2:3) to give F as an orange oil.
- N-bromosuccinimide (NBS) solid (98 mg, 0.26 mmol) is added to a solution of compound G (0.5 mmol) in 15 mL of CCI4. Radical initiator benzoyl peroxide (2 mol%) is subsequently added. The flask is placed into a 90 °C oil bath. After 10 min stirring, the reaction is complete. Filtration of the mixture through a celite pad, and evaporation of the filtrate gives a residue. Purification by chromatography (EtOAc:hexane, 1:3 to 1 :1) affords compound K.
- Pd(PPh3)4 (0.0177g, 0.015 mmol) is added to a solution of stannylimidazole D (0.51 g, 0.80 mmol), 2-nitro-4-methoxyphenol triflate O (0.33 g, 1.1 mmol), and LiCl (0.087 g, 2.1 mmol) in anhydrous dioxane (4.0 mL) at room temperature.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL14630600A IL146306A0 (en) | 1999-05-19 | 2000-05-16 | Process for making fused-ring imidazo-containing compounds |
AU48522/00A AU4852200A (en) | 1999-05-19 | 2000-05-16 | Process for making fused-ring imidazo-containing compounds |
EP00930759A EP1178989A1 (en) | 1999-05-19 | 2000-05-16 | Process for making fused-ring imidazo-containing compounds |
JP2000618274A JP2002544276A (en) | 1999-05-19 | 2000-05-16 | Method for producing fused ring imidazo-containing compound |
CA002372469A CA2372469A1 (en) | 1999-05-19 | 2000-05-16 | Process for making fused-ring imidazo-containing compounds |
NO20015588A NO20015588D0 (en) | 1999-05-19 | 2001-11-15 | Process for preparing imidazo-containing compounds with condensed ring |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13482999P | 1999-05-19 | 1999-05-19 | |
US60/134,829 | 1999-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000069857A1 true WO2000069857A1 (en) | 2000-11-23 |
Family
ID=22465213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/013417 WO2000069857A1 (en) | 1999-05-19 | 2000-05-16 | Process for making fused-ring imidazo-containing compounds |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1178989A1 (en) |
JP (1) | JP2002544276A (en) |
AU (1) | AU4852200A (en) |
CA (1) | CA2372469A1 (en) |
IL (1) | IL146306A0 (en) |
NO (1) | NO20015588D0 (en) |
WO (1) | WO2000069857A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6552033B1 (en) | 2000-05-16 | 2003-04-22 | The Procter & Gamble Co. | Imidazo-containing heterocyclic compounds, their compositions and uses |
-
2000
- 2000-05-16 CA CA002372469A patent/CA2372469A1/en not_active Abandoned
- 2000-05-16 IL IL14630600A patent/IL146306A0/en unknown
- 2000-05-16 EP EP00930759A patent/EP1178989A1/en not_active Withdrawn
- 2000-05-16 JP JP2000618274A patent/JP2002544276A/en not_active Withdrawn
- 2000-05-16 WO PCT/US2000/013417 patent/WO2000069857A1/en not_active Application Discontinuation
- 2000-05-16 AU AU48522/00A patent/AU4852200A/en not_active Abandoned
-
2001
- 2001-11-15 NO NO20015588A patent/NO20015588D0/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
MOLINA P, ET AL: "An anomalous intramolecular conjugate addition of N-protected imidazoles to vinyliminophosphoranes promoted by tetrabutylammonium fluoride. X-Ray crystal structure of 5-ethoxycarbonyl-5-(triphenylphosphoranylideneamino)-5,6-dihydroimidazo[2,1-a]isoquinoline", TETRAHEDRON., vol. 52, no. 43, 1996, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM., NL, pages 13671 - 13680, XP002149340, ISSN: 0040-4020 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6552033B1 (en) | 2000-05-16 | 2003-04-22 | The Procter & Gamble Co. | Imidazo-containing heterocyclic compounds, their compositions and uses |
Also Published As
Publication number | Publication date |
---|---|
AU4852200A (en) | 2000-12-05 |
CA2372469A1 (en) | 2000-11-23 |
NO20015588L (en) | 2001-11-15 |
IL146306A0 (en) | 2002-07-25 |
EP1178989A1 (en) | 2002-02-13 |
JP2002544276A (en) | 2002-12-24 |
NO20015588D0 (en) | 2001-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL177730B1 (en) | Galantamine derivatives, method of obtaining them and pharmaceutical composition | |
CN115010644B (en) | Preparation method of 2, 3-disubstituted indoline compound | |
EP1178989A1 (en) | Process for making fused-ring imidazo-containing compounds | |
CN113717197B (en) | Preparation method and application of antituberculosis drug Pretomoid | |
DE3504045C2 (en) | ||
SU786902A3 (en) | Method of preparing 6-amino-2',3',5',6'-tetrahydro-spiro-/penam-2,4'-/4h/thio/pyran/-3-carboxylic acid or its ester | |
WO2017023124A1 (en) | Novel method for preparing chromanol derivative | |
JP3046258B2 (en) | Method for producing 1-chlorocarbonyl-4-piperidinopiperidine or hydrochloride thereof | |
CN114195748B (en) | Preparation method of sodium-glucose cotransporter 2 inhibitor | |
IT201800006337A1 (en) | LIFITEGRAST PREPARATION PROCEDURE | |
US20020147190A1 (en) | Process for preparing 6-aryl-4H-S-triazolo[3,4-c]-thieno[2,3-e]-1,4-diazepines | |
JPH07119211B2 (en) | Preparation of 2-oxindole-1-carboxamide | |
JPS595595B2 (en) | Method for producing 15-hydroxyimino-E-homoebrunane derivative | |
JPH078860B2 (en) | Pyrazole derivative and method for producing the same | |
JPH0344073B2 (en) | ||
JP4004082B2 (en) | Method for producing cyclic nitroguanidine derivatives | |
CN113045568A (en) | Method for preparing gamma-eudiosmin U | |
PL189248B1 (en) | Method of obtaining 1-(p-methoxybenzooyl)-2-pyrolydone | |
JP4447741B2 (en) | Method for producing 1- (thiazolin-2-yl) azetidine derivative | |
KR0141657B1 (en) | Optically active 1-phenylpyrrolidone derivatives | |
KR100348100B1 (en) | Manufacturing method of 2-[(2,6-dichlorophenyl) amino] phenylacetoxyacetic acid | |
KR900001080B1 (en) | A preparation process for pyrazolone derivatives | |
CN117720456A (en) | New method for synthesizing apixaban intermediate 3, 3-dichloro-1- (4-substituted phenyl) piperidine-2-ketone | |
CN117903065A (en) | Synthesis method of 2-sulfonyl pyrimidine-4-carboxamide compound II | |
CN117658872A (en) | Synthesis process of 1, 3-dihydroxy-1-p-methylsulfonyl propiophenone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/01046/DE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 515299 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2000 618274 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2372469 Country of ref document: CA Ref document number: 2372469 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 48522/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000930759 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000930759 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09979561 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000930759 Country of ref document: EP |